DADC
MRNA icon

D.A. Davidson & Co’s Moderna MRNA Stock Holding History

D.A. Davidson & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8M Sell
54,290
-1,107
-2% -$57.3K 0.02% 509
2026
Q1 		$2.81M Sell
55,397
-28,170
-34% -$1.31M 0.02% 576
2025
Q4 		$2.46M Sell
83,567
-6,254
-7% -$170K 0.02% 596
2025
Q3 		$2.32M Buy
89,821
+10,217
+13% +$285K 0.01% 603
2025
Q2 		$2.2M Buy
79,604
+62,778
+373% +$1.65M 0.02% 582
2025
Q1 		$477K Buy
16,826
+99
+0.6% +$3.51K ﹤0.01% 1045
2024
Q4 		$696K Sell
16,727
-23,210
-58% -$1.11M 0.01% 904
2024
Q3 		$2.67M Buy
39,937
+5,565
+16% +$511K 0.02% 482
2024
Q2 		$4.08M Sell
34,372
-1,569
-4% -$199K 0.04% 347
2024
Q1 		$3.83M Buy
35,941
+2,840
+9% +$286K 0.03% 360
2023
Q4 		$3.29M Buy
33,101
+22,988
+227% +$1.93M 0.03% 369
2023
Q3 		$1.04M Buy
10,113
+827
+9% +$92.2K 0.01% 670
2023
Q2 		$1.13M Buy
9,286
+342
+4% +$45.6K 0.01% 654
2023
Q1 		$1.37M Sell
8,944
-5,937
-40% -$979K 0.02% 567
2022
Q4 		$2.67M Buy
14,881
+7,208
+94% +$1.18M 0.03% 377
2022
Q3 		$907K Buy
7,673
+25
+0.3% +$3.79K 0.01% 608
2022
Q2 		$1.09M Buy
7,648
+413
+6% +$59K 0.01% 569
2022
Q1 		$1.25M Buy
7,235
+92
+1% +$15.5K 0.01% 584
2021
Q4 		$1.81M Buy
7,143
+1,600
+29% +$468K 0.02% 484
2021
Q3 		$2.13M Buy
5,543
+643
+13% +$237K 0.02% 413
2021
Q2 		$1.15M Sell
4,900
-131
-3% -$23.4K 0.01% 586
2021
Q1 		$659K Sell
5,031
-2,187
-30% -$317K 0.01% 711
2020
Q4 		$754K Buy
+7,218
New +$730K 0.01% 578

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

D.A. Davidson & Co's MRNA Position: Q2 2026 in Review

D.A. Davidson & Co reduced its Moderna (MRNA) stake by 2% in Q2 2026, selling an estimated $57.3K and leaving 54,290 shares worth $3.8M. The position accounts for 0.02% of the portfolio, ranked #509.

D.A. Davidson & Co first reported a position in MRNA in Q4 2020 and has held it in 23 quarters since. The position peaked at $4.08M in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • D.A. Davidson & Co held 54,290 shares of Moderna worth $3.8M as of Q2 2026.
  • D.A. Davidson & Co sold 1,107 Moderna shares in Q2 2026, an estimated $57.3K.
  • Moderna made up 0.02% of D.A. Davidson & Co's portfolio in Q2 2026, its #509 holding.
  • D.A. Davidson & Co first reported a position in Moderna in Q4 2020 and has held it in 23 quarters since.
  • D.A. Davidson & Co's Moderna position peaked at $4.08M in Q2 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.